Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus AG for borderline resectable pancreatic cancer
NCT06944106Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in pancreatic cancer (PC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: R0 and R1 resection rates at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06944106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944106.